Category Archives: Regulatory

06Jan/17
WP2 Main Image Strategic Leadership

Industry Executives Discuss Change in a Complex Environment

By: Sandra K. Rodriguez, Market Analyst

Life Science Industry Executive Roundtable – Event Brief

ert-picComplex – the one word that accurately describes the current environment in Life-Sciences. As products and manufacturing processes become more complex, managing change comes with a higher level of risk.  To discuss the importance of managing change in this complex environment, as well as examine key findings from our latest research on Change and Configuration Management, Axendia brought together a select group of executives from leading Life Science companies for a roundtable in Princeton, NJ.

A primary thread of the discussion was the need for closed-loop Change and Configuration Management (C&CM) strategies.  Closing the loop is becoming critical to ensuring product quality throughout the product lifecycle.

The research shows that:

  • 63% of survey respondents say their C&CM process is only somewhat effective or useless
  • Not a single respondent reported they have an idealC&CM system in place
  • 55%report that a slow and cumbersome C&CM process keeps them up at night
  • 62% rateregulatory and government agencies as their TOP business disruptor

Continue reading

04Jan/17
quality

Is Your Quality Unit Ready to Submit Quality Metrics Data Across Your Supply Chain?

By: Sandra K. Rodriguez, Market Analyst

FDA “Encourages” Industry to Volunteer for e-Inspections Program

Based on Quality Metrics, FDA’s e-Inspections program is encouraging industry to implement state-of-the-art, innovative quality management systems for pharmaceutical manufacturing.    In response to stakeholder feedback, the agency issued a revised draft guidance document in November 2016 titled “Submission of Quality Metrics Data[1].”

The draft guidance explains how the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) intend to utilize submitted data and quality metrics to help ensure that their policies and practices continue to support continuous improvement and innovation in the pharmaceutical manufacturing industry.  For more background on the evolution of this initiative see ISPE, FDA and the Metrics Future and FDA to Grade Industry on a Curve – Are You Ready?
Continue reading

29Sep/16
gudid

Hear Directly from FDA: Are You Done with UDI or Is This Just the Beginning?

Webinar Announcement 

Are you done with UDI… or is it just the beginning?  Hear directly from FDA’s Senior Advisor for UDI and Industry Experts the profound effect UDI implementation will have on Med-Tech manufacturers, healthcare providers, regulators and ultimately the patient.

On Oct. 13th at 1:30pm Eastern, join Terrie Reed, Senior Advisor for UDI Adoption at the FDADaniel R. Matlis of Axendia, and Jean Colombel of Dassault Systemes as they discuss UDI and how its value resides in the ability to optimize meaningful data collection and analysis.

Continue reading

27Sep/16
man-jumping-over-the-ledge-wp4

Don’t Solve Quality Problems, Avoid Them

New White Paper: The Future of Change and Configuration Management in the Med-Tech Industry

Can you distribute poor quality products while complying with all applicable regulatory requirements? Sure! After all, you can conduct a recall of poor quality products in compliance with all applicable regulations.  FDA’s Top Medical Device official agrees.

Jeff Shuren, M.D., J.D., Director of FDA’s Center for Devices and Radiological Health (CDRH), put it this way: “…one device manufacturer can meet FDA requirements and still make a poor quality device; whereas, a second manufacturer may not comply with all FDA requirements and yet make a high-quality device.”

Is your organization focused on Solving Quality Problems or Avoiding Them?  Download the white paper to find out how Med-Tech Innovators have been able to shift their focus on improving market presence, manufacturing processes and product quality.

Contact: research@axendia.com to see if you qualify for a complimentary access code and save $499.
21Sep/16
Data Integrity in LS

Data Integrity – A Requirement for FDA Compliance, Quality and Beyond

On Demand Webinar Announced

Data integrity and quality are foundational for regulatory compliance and good science, an issue that was recently highlighted by the new “FDA Guidance for Data Integrity and Compliance with cGMP”. This guidance was issued to address a growing number of data integrity violations and underscores the importance of data quality and integrity to support intellectual property protection and patient filings in regulated and non-regulated spaces.

DownloadData Integrity in Life Sciences a PDF of this inforgraphic.

We discuss what Goldilocks and Life-Sciences companies have in common during the webinar. An on demand recording is available here.